iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan‐L study
Globally, nearly half of patients with type 2 diabetes (T2D) do not successfully achieve target HbA1c with basal insulin, despite meeting fasting plasma glucose (FPG) targets. In this post hoc analysis of the LixiLan‐L study, we determined whether iGlarLixi, a fixed‐ratio combination of insulin glar...
Gespeichert in:
Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2020-09, Vol.22 (9), p.1683-1689 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Globally, nearly half of patients with type 2 diabetes (T2D) do not successfully achieve target HbA1c with basal insulin, despite meeting fasting plasma glucose (FPG) targets. In this post hoc analysis of the LixiLan‐L study, we determined whether iGlarLixi, a fixed‐ratio combination of insulin glargine Gla‐100 (iGlar) and the glucagon‐like peptide‐1 receptor agonist lixisenatide (Lixi), addresses the challenge of reducing residual hyperglycaemia in patients with T2D. In LixiLan‐L, a randomized, open‐label study, 1018 patients with T2D on basal insulin for ≥6 months ± oral antidiabetes drugs entered a 6‐week run‐in period, during which they were switched to and/or optimized for a daily dose of iGlar while continuing only metformin. Following the run‐in period, 736 patients were then randomized to receive iGlarLixi or were continued on iGlar for 30 weeks ± metformin. Residual hyperglycaemia was defined as HbA1c ≥ 7.0% despite FPG of |
---|---|
ISSN: | 1462-8902 1463-1326 |
DOI: | 10.1111/dom.14077 |